Developed by Affymax, the FDA-approved OMONTYS is a synthetic, pegylated erythropoiesis-stimulating agent (ESA) that is peptide-based and its building blocks (amino acids) are arranged in a different order than erythropoietin.
Under the deal, DSI agreed to adopt OMONTYS and treat CKD patients within its selected dialysis centers and then, based on experience, will evaluate the potential to expand to additional centers.
The deal also allows DSI Renal to provide the product for discounts and rebates, subject to certain requirements.
Affymax chief executive officer John Orwin said, "With this agreement, we now have supply agreements in place with five out of the six medium-sized dialysis organizations in the U.S."
Financial details of the deal have not been disclosed.